



# REGENERATIVE MEDICINE

LIGHTING THE PATH TO DISCOVERY

Eagle Global Scientific, LLC (EGS) is a certified 8(a) Alaska Native Corporation (ANC) that contracts with federal agencies and military partners through both the direct award and competitive procurement processes. We work with experts in regenerative medicine to circumvent the immune responses associated with conventional medical technology by using the patient's own cells rather than artificial or natural materials that are unfamiliar to the body. EGS' developments in this field revolutionize the use of stem cells to restore healthy organ and tissue function; this therapy represents one of the most promising areas for the next generation of groundbreaking treatments.

As a small business, EGS is singularly qualified to support federal programs in spheres where previously only large companies have been players. Our 8(a) status allows EGS to accept direct awards (sole-source contracts) up to \$22 million. Awards to an 8(a) ANC cannot be protested. EGS is fully on-ramped to both the OASIS SB Pool 4 and the SB 8(a) SubPool 4 (NAICS 541715 Scientific Services) contracts.

## WORK WITH US

### *SBA CONTACT*

Please [contact us](#) directly for more information on our SBA Officer.

### *EAGLE GLOBAL SCIENTIFIC*

SBA Certified 8(a) Contractor  
Primary NAICS: 621511  
EGS DUNS: 080-02-2933  
EGS Cage Code: 7GWG7  
OASIS Pool 4  
OASIS SB 8(a) SubPool 4

## MILITARY REGMED SUPPORT

EGS provides senior scientists and biomedical engineers to lead Trauma and Clinical Care Research (TCCR) for the U.S. Air Force Trauma and Resuscitation Research Program (AFT2R). EGS also manages animal and live tissue studies in the fields of hemorrhage, resuscitation, endovascular technologies, extra-corporeal life support, and molecular biology. Our work in this program leads to novel treatments that can greatly enhance the generation of new tissue needed for wounds sustained in battlefield combat.

## STEM CELL TECHNOLOGY ADVOCACY

EGS is a dedicated supporter of regenerative medicine and ethical stem cell research through our membership in the Genetics Policy Institute and Regenerative Medicine Foundation. Additionally, EGS has been a proud sponsor of the World Stem Cell Summit since 2014.

The REGROW Act modernizes FDA's current regulatory approach toward safe and effective cell therapies, while protecting approval pathways under sections 351 and 361 of the Public Health Service Act. The REGROW Act



*Lighting the Path  
to Discovery*

also aligns with recommendations included in Bipartisan Policy Center's report entitled *Advancing Regenerative Cellular Therapy: Medical Innovation for Healthier Americans*.

## STEM CELL INDUSTRY COLLABORATION

EGS has partnered with SYNVIVO, a CFD Research Corporation Life Science company located within the Hudson Alpha Institute for Biotechnology, in a DoD funded project to further develop CFDR's Integrated Stem Cell Impedance Analyzer (iSCIA). This novel medical diagnostic device can directly detect the differentiation state of a mixed population of stem cells in a non-invasive manner and provide a purified stream of differentiated cells that can then be used therapeutically in a clinical setting at a higher yield and lower cost.

## PARTNERS

- U.S. Air Force Trauma and Resuscitation Research Program (AFT2R)
- Department of Defense (DoD)
- Centers for Disease Control and Prevention (CDC)
- Genetics Policy Institute
- Regenerative Medicine Foundation
- World Stem Cell Summit
- Hudson Alpha Institute for Biotechnology
- SynVivo

[Learn more](#) about our past performance.

## LOCAL LEADERSHIP

*EGS ATLANTA OFFICE*  
2835 Brandywine Rd.  
Suite 200  
Atlanta, GA 30341

*VP FOR LIFE SCIENCES*  
James M. Watt, PhD  
Atlanta, GA  
205.213.0967  
james.watt@eglobal.science